95% of Noteholders Agree to Convert $14.1M of Debt, $1.2M New Capital Funded
NXGL sits 19% above its 52-week low of $3.
Summary
Noteholders holding about $14.125 million of NEXGEL's $14.885 million convertible note principal — roughly 95% — have signed agreements to convert into common stock, contingent on completing a strategic merger. That would wipe out most of the debt load that carried a going-concern warning and potential default risk in the Q2 10-Q. Existing noteholders and strategic partner Sequence LifeScience committed about $1.276 million, with $1.2 million funded to date, buying common stock at $5.50 a share with 100% warrant coverage at $10.00. Sequence put in about $732,000, or 61% of the funded amount, and is wholly owned by Interim CEO Brian Kieser — a related-party financing. Management also says it has implemented about $2.25 million of annualized cost savings and is chasing up to $1.75 million more. The catch: if the Fountainhead LifeSciences merger (also a related-party deal) is not done by March 31, 2027, the conversions do not happen, the notes stay outstanding, and the new shares convert back into notes.
At the time of this announcement, NXGL was trading at $3.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11M. The 52-week trading range was $3.00 to $51.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.